Share price · JNJ
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when JNJ's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 22 Oct 2026+3.8%
- 13 Oct 2026-5.7%
- 5 Oct 2026-1.2%
- 22 Jul 2026+2.0%
Nothing announced by JNJ that day or the session before.
- 15 Jul 2026-2.7%
- 23 Jun 2026+3.4%
Nothing announced by JNJ that day or the session before.
- 13 May 2026+2.7%
Nothing announced by JNJ that day or the session before.
- 23 Apr 2026+2.0%
- 28 Jan 2026+1.5%
- 13 Jan 2026+1.9%
Share of unusual movement by asset
For each asset, the share of JNJ's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(57 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | EGFR x c-METMultispecific antibody | Non-Small Cell Lung CancerColorectal CancerHead and Neck Squamous Cell Carcinoma | |
Bosentan(Tracleer) | Approved | Endothelin receptor (ETA/ETB, dual)Small molecule | Pulmonary Arterial HypertensionSystemic Sclerosis |
Canagliflozin(Invokana) | Approved | SGLT2Small molecule | Type 2 DiabetesChronic Kidney Disease |
| Approved | BCMACell therapy | Multiple Myeloma | |
| Approved | CD38Monoclonal antibody | Multiple MyelomaAmyloidosis AL Amyloidosis | |
Darunavir(Prezista) | Approved | HIV proteaseSmall molecule | HIV |
| Approved | FGFR1-4Small molecule | Non-Small Cell Lung CancerBladder / Urothelial Cancer Urothelial Carcinoma | |
Esketamine(Spravato) | Approved | NMDA receptorSmall molecule | Major Depressive Disorder |
Etravirine(Intelence) | Approved | HIV reverse transcriptaseSmall molecule | HIV |
golimumab(Simponi) | Approved | TNF-alphaMonoclonal antibody | Inflammatory Bowel DiseasePsoriatic ArthritisRheumatoid Arthritis Ulcerative Colitis, Crohn's Disease |
guselkumab(Tremfya) | Approved | IL-23 p19Monoclonal antibody | Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasis Ulcerative Colitis, Crohn's Disease |
| Approved | Dopamine D2 receptor (antagonist)Small molecule | Schizophrenia | |
| Approved | BTKSmall molecule | Diffuse Large B-Cell LymphomaGraft-versus-Host DiseaseMantle Cell LymphomaChronic Lymphocytic Leukemia Chronic Graft-versus-Host Disease | |
icotrokinra(Icotyde) | Approved | IL-23 receptorPeptide | Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasis Ulcerative Colitis, Crohn's Disease |
infliximab(Remicade) | Approved | TNF-alphaMonoclonal antibody | Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasisRheumatoid Arthritis Ulcerative Colitis, Crohn's Disease |
Discontinued programmes (1)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
(75 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (5)
December 2026 (5)
2027 (26)
January 2027 (2)
February 2027 (3)
March 2027 (2)
April 2027 (3)
May 2027 (1)
What to watch
June 2027 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
July 2027 (1)
What to watch
August 2027 (2)
September 2027 (1)
What to watch
October 2027 (2)
November 2027 (1)
What to watch
2028 (22)
January 2028 (1)
What to watch
February 2028 (1)
What to watch
March 2028 (2)
April 2028 (2)
June 2028 (3)
August 2028 (4)
September 2028 (2)
November 2028 (2)
December 2028 (5)
2029 (10)
January 2029 (1)
What to watch
February 2029 (1)
What to watch
April 2029 (1)
What to watch
May 2029 (2)
June 2029 (2)
2030 (5)
February 2030 (1)
What to watch
May 2030 (1)
What to watch
2031 (4)
April 2031 (2)
October 2031 (1)
What to watch
December 2031 (1)
What to watch
2032 (2)
2037 (1)
January 2037 (1)
What to watch
Regulatory and conference events
(52)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
The 12 most recent of 52 past events are shown.
Financial reports
Quarterly & interim (20)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $25.4B | $4.7B | $16.9B+ $318M short-term inv. | —$7.7B operating cash flow | report ↗ |
View 19 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $25.3B | $3.7B | $20.4B+ $336M short-term inv. | —$8.6B operating cash flow | report ↗ |
| 2026-Q1 | $24.1B | $3.5B | $22.1B+ $363M short-term inv. | —$2.5B operating cash flow | report ↗ |
| 2025-Q4 | $24.6B | $4.3B | $20.1B | — | report ↗ |
| 2025-Q3 | $24.0B | $3.7B | $18.6B+ $331M short-term inv. | —$9.2B operating cash flow | report ↗ |
| 2025-Q2 | $23.7B | $3.5B | $18.9B+ $303M short-term inv. | —$3.9B operating cash flow | report ↗ |
| 2025-Q1 | $21.9B | $3.2B | $38.8B+ $307M short-term inv. | —$4.2B operating cash flow | report ↗ |
| 2024-Q4 | $22.5B | $5.3B | $24.5B | — | report ↗ |
| 2024-Q3 | $22.5B | $5.0B | $20.3B+ $317M short-term inv. | —$8.0B operating cash flow | report ↗ |
| 2024-Q2 | $22.4B | $3.4B | $25.5B+ $597M short-term inv. | —$5.6B operating cash flow | report ↗ |
| 2024-Q1 | $21.4B | $3.5B | $25.5B+ $745M short-term inv. | —$3.7B operating cash flow | report ↗ |
| 2023-Q4 | $21.4B | $3.4B | $19.7B+ $3.8B short-term inv. | —$7.5B operating cash flow | report ↗ |
| 2023-Q3 | $25.5B | $3.8B | $21.2B+ $7.3B short-term inv. | —$4.2B operating cash flow | report ↗ |
| 2023-Q2 | $24.7B | $3.6B | $26.9B+ $5.4B short-term inv. | $68M$3.3B operating cash flow | report ↗ |
| 2023-Q1 | $19.9B | — | $14.1B+ $9.4B short-term inv. | —$5.3B operating cash flow | report ↗ |
| 2022-Q4 | $23.8B | $3.6B | $11.4B+ $22.7B short-term inv. | —$6.3B operating cash flow | report ↗ |
| 2022-Q3 | $24.0B | $3.7B | $11.0B+ $21.6B short-term inv. | —$5.6B operating cash flow | report ↗ |
| 2022-Q2 | $23.4B | $3.5B | $10.5B+ $19.9B short-term inv. | —$4.0B operating cash flow | report ↗ |
| 2021-Q4 | $23.3B | $3.4B | $17.6B+ $13.4B short-term inv. | —$8.3B operating cash flow | report ↗ |
| 2021-Q3 | $23.3B | $3.4B | $14.3B+ $11.0B short-term inv. | —$5.3B operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $94.2B | $14.7B | $20.1B+ $393M short-term inv. | —$24.5B operating cash flow | report ↗ |
Reported revenue was $94,193M, up 6.0% YoY, with U.S. sales of $53.8B and international sales of $40.4B. R&D spend was $14,665M, down 14.9% YoY; cash, cash equivalents and marketable securities totaled $20.1B at year-end. Net income was $26,804M.
Although no formal financial guidance was provided, management said continued global launches of STELARA biosimilars would keep pressuring sales and expected generic OPSUMIT entry in 2026 could significantly reduce future sales. The company completed the Intra-Cellular Therapies acquisition in April 2025, announced a planned Orthopaedics separation in October 2025 with a targeted completion within 18–24 months, and expected a MedTech Surgery restructuring to be substantially complete by the end of fiscal 2026. Pipeline activity included numerous regulatory approvals and filings across products such as DARZALEX, TREMFYA, SPRAVATO, RYBREVANT, CAPLYTA, ICOTYDE, and IMAAVY, while the company also reversed approximately $7.0B of a previously accrued talc reserve.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $88.8B | $17.2B | $24.5B+ $417M short-term inv. | —$24.3B operating cash flow | report ↗ |
| 2023-FY | $85.2B | $15.1B | $22.9B+ $9.4B short-term inv. | —$21.2B operating cash flow | report ↗ |
| 2022-FY | $93.8B | $14.7B | $14.5B+ $17.1B short-term inv. | —$23.4B operating cash flow | report ↗ |
| 2021-FY | $82.6B | $12.2B | $14.0B+ $11.2B short-term inv. | —$23.5B operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 1 purchase ($258K), 29 sales ($154.4M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-12 | Forminard Elizabeth · EVP, Chief Legal Officer | Option exercise | 13,072 | $151.41 | $2.0M | Form 4 |
| 2026-11-12 | Forminard Elizabeth · EVP, Chief Legal Officer | Open-market sale | 13,072 | $284.39 | $3.7M | Form 4 |
| 2026-11-12 | Forminard Elizabeth · EVP, Chief Legal Officer | Option exercise (derivative) | 13,072 | — | — | Form 4 |
| 2026-09-08 | HEWSON MARILLYN A · director | Award / grant (derivative) | 180.956 | $276.31 | $50K | Form 4 |
| 2026-09-08 | Woods Eugene A. · director | Award / grant (derivative) | 135.717 | $276.31 | $37K | Form 4 |
| 2026-09-08 | Pinto Daniel E · director | Award / grant (derivative) | 113.098 | $276.31 | $31K | Form 4 |
| 2026-09-02 | Schmid Timothy · EVP, WW Chair, MedTech | Option exercise | 11,070 | $131.94 | $1.5M | Form 4 |
| 2026-09-02 | Schmid Timothy · EVP, WW Chair, MedTech | Open-market sale | 11,070 | $274.74 | $3.0M | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 4,578 reporting institutions held 1772.2M shares ($418.0B, 73.6% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 213,385,546 | $52.2B |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 156,605,370 | $38.3B |
| 3 | STATE STREET CORP | 133,476,288 | $32.6B |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 63,514,436 | $15.5B |
| 5 | JPMORGAN CHASE & CO | 63,096,344 | $15.3B |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 59,164,862 | $14.4B |
| 7 | MORGAN STANLEY | 44,721,167 | $10.9B |
| 8 | STATE FARM MUTUAL AUTOMOBILE INSURANCE CO | 31,590,952 | $7.7B |
| 9 | NORTHERN TRUST CORP | 29,319,669 | $7.2B |
| 10 | BANK OF AMERICA CORP /DE/ | 25,516,697 | $6.2B |
| 11 | FMR LLC | 24,771,828 | $6.1B |
| 12 | Bank of New York Mellon Corp | 21,821,962 | $5.3B |
| 13 | WELLINGTON MANAGEMENT GROUP LLP | 20,075,375 | $4.9B |
| 14 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 19,628,113 | $4.8B |
| 15 | Legal & General Group Plc | 19,347,862 | $4.7B |